Schema-Root.org logo

 

  cross-referenced news and research resources about

 AstraZeneca

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Tue. December 12, 2017 reload page to refresh

-
AstraZeneca (nyse: AZN) is one of 103 public companies in the "pharmaceuticals" industry, but how does it compare to its rivals? We will compare AstraZeneca to related companies based on the strength of its institutional ownership, earnings, valuation, analyst recommendations, profitability, dividends ...
New rival AstraZeneca, of course, can't yet tout long-term data for its own drug Calquence, which snagged an FDA approval in MCL in late October. But it's hoping to ride strong results from the trial that helped it snag approval, in which Calquence provoked an overall response rate of 81% and a complete ...
"Our mission with Survivors Have Heart is that these stories are heard and that patients can feel a connection to one another's journey to enable them to continue to play an active role to reduce the risk of having another heart attack," said Kiersten Combs, AstraZeneca executive director, cardiovascular, ...
British drug giants AstraZeneca and GSK have stepped up their fightback in the global race to find cures for blood cancers after two key clinical trials showed encouraging results. The FTSE 100 duo are presenting findings on the effectiveness of their medicines at a leading blood cancer event in Atlanta this ...

As Theresa may reached a Brexit divorce deal with the EU, the drugs giant AstraZeneca was fretting about whether leaving the bloc would harm the fight against cancer. In a letter to MPs this week, the Cambridge-based Anglo-Swedish multinational warned it could be hit by an extra £26.4 million a year in ...
Anthony Johnson, M.D., AstraZeneca's head of early clinical development for the Innovative Medicines and Early Development Biotech unit, has taken the top job. He also once held similar roles at Bristol-Myers Squibb and GlaxoSmithKline but is also familiar with the environment of early-stage biotech with ...
AstraZeneca PLC logo Jefferies Group restated their hold rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on ...
AstraZeneca Plc. AZN announced that the European Medicines Agency (EMA) has accepted a variation to the marketing Authorisation ...
27, 2017, AstraZeneca announced that it is establishing a strategic joint venture with the Chinese Future Industry investment fund (FIIF) to form ...
AstraZeneca plc has handed over an exclusive worldwide license to a pre-clinical reversal agent for its blood thinner Brilinta. The agent ...
AstraZeneca PLC (AZN.LN) said Tuesday that the European Medicines Agency has accepted a variation to its marketing-authorization ...
G1 will collaborate with AstraZeneca on a new clinical trial evaluating AstraZeneca's drug Tagrisso in combination with G1's drug candidate ...
AstraZeneca said Monday it has formed a strategic joint venture with the Chinese Future Industry investment fund (FIIF) to create a stand-alone ...
Shares of AstraZeneca PLC (STO:AZN) last traded at 556.5, representing a move of -0.71%, or -4 per share, on volume of 119,995 shares.
AstraZeneca PLC logo BMO capital markets set a $38.00 target price on AstraZeneca PLC (nyse:AZN) in a research note released on ...

AstraZeneca is allowing U.K. scientists access to an early-stage pipeline med in the hope it can help patients with head and neck cancer.
AstraZeneca has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company ...
AstraZeneca, plc AZN announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...
AstraZeneca's drug sales fell again in the third quarter, hit by generic competition to former blockbusters like cholesterol pill Crestorp. The pace ...
After a failed trial in May, AstraZeneca hoped tralokinumab could pass subpopulation tests and make it to the finish line, but it wasn't meant to ...
AstraZeneca PLC logo Citigroup Inc. upgraded shares of AstraZeneca PLC (nyse:AZN) to a buy rating in a report published on Wednesday, ...
With approval pending for benralizumab, AstraZeneca is preparing to move into the respiratory biologics space--and it's not taking the task ...
AstraZeneca Plc (nyse:AZN) is a component of the 135 company pharmaceuticals GICS industry group, which is a segment of the 783 ...
Roivant sciences has licensed a deprioritized investigational candidate from AstraZeneca. The deal gives Roivant, Axovant's parent company, ...
The PTEN gene controls cell growth and behavior, with its loss implicated in cancer. AstraZeneca and Babraham have collaborated to improve ...
AstraZeneca PLC (AZN) is attracting attention this week on the back of news that the company has scored a priority review from the FDA for an ...
People are turning down jobs at AstraZeneca because of uncertainty about their right to stay in the United Kingdom after Brexit, according to ...
AstraZeneca has handed over global rights to an unspecified drug "outside of AstraZeneca's main therapy areas" for an unspecified deal ...
Headquartered in London, AstraZeneca (AZN) is a pharmaceutical company with operations in over 100 countries. The company is involved in ...
AstraZeneca PLC (AZN.LN) on Wednesday said that the U.S. Food & Drug Administration has granted a priority review to its new drug ...
Goldfinch poaches AstraZeneca research executive Tony Johnson for CEO. by Phil Taylor |. Dec 5, 2017 7:30am. Johnson will be joined at Goldfinch by another Big PhaRMA veteran, Mike Broxson, who was most recently head of R&D business development at Takeda. Share facebook twitter LinkedIn email Print. The lure ...
AstraZeneca has had trouble easing concerns about its immuno-oncology portfolio, but a new editorial in the New England Journal of Medicine ...
London -- An unlisted Swiss biotech company focused on developing "armed antibodies" to fight cancer has raised $200 million (£152 ...
AstraZeneca PLC (AZN.LN) has received approval from the U.S. Food and Drug Administration for a new formulation of its type-2 diabetes ...
Back in 2015, AstraZeneca bought a majority stake in blood cancer biotech Acerta for $4 billion. But over the weekend, it said that some early ...
AstraZeneca has posted preliminary phase 1b/2 data on the use of savolitinib in combination with Iressa or Tagrisso. Adding the MET tyrosine ...
AstraZeneca PLC (nyse:AZN) closed its last session at $34.23. The stock traded within a range of $33.97 and $34.23. The company operates ...
AstraZeneca's next big cancer drug linked to falsified preclinical data; Harmony raises $270M, nabs development rights to narcolepsy drug.
Currently, AstraZeneca Plc (nyse:AZN) has a Sell using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing ...
AstraZeneca, meanwhile, asked if FDA might consider harmonizing the assessment process of the changes relating to continuous ...
NewLink genetics Corp. has hooked up with AstraZeneca plc to study the safety and efficacy of combining its small molecule IDO pathway ...
Earlier this month, AstraZeneca rolled out positive results for a LAMA/LABA combo COPD med it hopes to bring to the U.S. market. And now, it's ...
Bernstein Upgrades AstraZeneca (AZN) to Outperform ... Bernstein upgraded AstraZeneca (nyse: AZN) from market Perform to Outperform ...
Bernstein upgraded shares of AstraZeneca plc (ADR) (nyse: AZN), giving four reasons for its optimistic assessment. All the same, the firm also ...
Shares of U.K. drugmaker AstraZeneca (nyse:AZN) are in a rut. In contrast to much larger big PhaRMA peers like Pfizer (NYSE:PFE) and Merck ...
AstraZeneca PhaRMA saw a decrease of 3.5 points from today's opening price with the current price being Rs. 927.6 while a change of ...
Labcyte Inc. today announced that GSK has joined its consortium with AstraZeneca to combine acoustic liquid dispensing technology from ...


 

news and opinion


 


 


 


 


schema-root.org

     astrazeneca

pharmaceutical industry:
     ariad
     astrazeneca
     baxter
     eli lilly
     glaxosmithkline
     merck
     mylan
     novartis
     pfizer
     products
     research
     takeda
     upjohn
     valeant